

# Lyme Disease in 2013: Lessons Learned in Diagnosis

John N. Aucott, M.D.

Assistant Professor, Department of Medicine

Johns Hopkins University School of Medicine


Lyme Disease Research Foundation

Park Medical, L.L.C.



10755 Falls Road, Suite 200

Lutherville, MD

# Untreated Lyme Disease is a Systemic Infection with both Early and Late Manifestations



# Lyme Disease is Defined by the Signs of Infection: Rash is “Diagnostic” Other Signs Require Serologic Confirmation




# Antibody Testing is Used to Confirm Infection

## CDC 2-Tier Strategy


**2-tier testing strategy is difficult for clinicians to understand and use**

- **2 step testing**
  - Elisa screening, Western blot for (+) Elisa
- **Criteria for (+) blot**
  - **Weeks 1-4: IgM 2/3 bands**
  - **> 4 weeks: IgG 5/10 bands**
- Surveillance strategy emphasizes specificity over sensitivity
- 40% sensitivity in first weeks
- CDC criteria requires (+) IgG western blot to be considered positive in illness of greater than 4 weeks duration, which further decreases sensitivity

### Western Blot



# Seronegative Windows in IgM and IgG Antibody Responses in Untreated Lyme disease




# Difficulties With Current Lyme Disease Diagnosis


- Challenges of early Lyme diagnostics at initial physician visit:
  - Serologic tests are insensitive during acute phase
  - Early diagnosis is based on accurate clinician identification of EM
  - Rash is not always present or recognized
  - Other symptoms such as fever and myalgia are non-specific, and do not distinguish Lyme from other infections
- Diagnosis of Early Lyme Disease is based on the Physician's ability to recognize Erythema Migrans
  - When EM is present, often atypical without stereotypical target or bull's-eye appearance
  - Disseminated cutaneous skin manifestations not widely recognized
  - Atypical manifestations of rash possible
- Lack of recognition results in under diagnosis

# 40% of Early Cases Aren't diagnosed and go on to Develop Late Lyme Disease

Clinical Manifestations of Confirmed Lyme Disease Cases--United States, 2001-2010




Physician recognition of diagnostic EM rash is  
imperfect. Feder H. *Am J Med* **99:41, 1995**  
Internet Survey of Erythema Migrans Identification








# Internet Survey of Erythema Migrans Identification



# The Majority of EM Lack the Typical Bull's Eye Appearance





# Disseminated Rash of Lyme Disease is atypical in appearance



# Improving Diagnosis in Lyme Disease

- Accurate Identification of EM
  - Starts with patient awareness and seeking care
  - Patient “misdiagnosis” of EM as spider bites, bruises, poison ivy, other skin conditions
  - Increasing clinician sensitivity/specificity for diagnosis of EM
- Biomarker improvement/discovery for confirmation of clinical diagnosis

# Strategy to Improve Early Diagnosis through increased recognition of Erythema Migrans

- Education with visual tools to show range of appearance of EM
- Protocol for thermal enhancement and photography for self diagnosis
- Use of photos to increase patient communication with physicians at earliest stage of Lyme disease

# Looking for a bull's-eye rash? Look again – erythema migrans can take many forms.



Most people do not see the tick that causes their Lyme disease. However, approximately 75% of patients with early Lyme disease will have the telltale skin lesion in the first 1-4 weeks of infection. The Lyme disease skin lesion is large, greater than 5 cm (2 inches), in size. It can be distinguished from an uninfected tick or bug bite because it lasts days or weeks and enlarges in size over time. When the skin lesion is present, it is a more accurate way to diagnose Lyme disease than by using the currently available blood tests.

Most clinicians recognize the classic target lesion or bull's-eye rash. However, most are not aware that the majority of Lyme disease skin lesions are uniformly red or reddish-blue. In late spring and early summer when early Lyme disease is most prevalent, any of the skin lesions shown here could be indicative of Lyme disease. Fever, chills, and muscular pain in the neck and extremities are common early Lyme disease symptoms. The presence of these symptoms with a rash should raise the suspicion of a Lyme disease diagnosis.



## Central Clearing/ Target Lesions

The classic bull's-eye target lesion of Lyme disease occurs in the minority of patients. The majority of Lyme disease skin lesions lack the hallmark rings and central clearing. **Only about 20% of Lyme disease lesions have a bull's-eye appearance.**



## Uniformly Red Lesions

Most Lyme disease skin lesions are uniformly red without the rings or target appearance. They are distinguished from other skin rashes by their round or oval shape and sharply demarcated borders. Skin lesions often hide in difficult to see places such as behind the knee or in the groin or armpit.



## Blistering Lesions - It's not a spider bite.

1% of Lyme disease skin lesions have a central blistering or pustular appearance that is commonly mistaken for a spider bite. Why does this occur? It is likely a more severe inflammatory reaction to *Borrelia burgdorferi* that results in skin blistering.



## Blue-Red Lesions

Some Lyme disease skin lesions have a blue-purple color and can be mistaken for a bruise. What distinguishes this from a bruise? The perfectly uniform circle and sharply demarcated border. They may be minimally pruritic or sensitive to touch but are not pruritic like poison ivy or extremely painful like shingles or cellulitis.



## Disseminated Lesions

These are not multiple tick bites. The original skin infection of Lyme disease can spread through the bloodstream to other areas of the body, including the joints, nervous system and other areas of the skin. This results in multiple skin lesions that often have variable shapes and appear throughout different areas of the skin.

## How to differentiate Lyme disease from other causes of fever and rash.


While viral illnesses and other bacterial infections can cause symptoms of fever, fatigue, and pain that mimic Lyme disease, they do not have large distinct round or oval rashes like Lyme disease. In addition, most viral illnesses have typical cold symptoms of runny nose or prominent cough which are not common in Lyme disease.

# Provider Education





What makes the EM rash easily visible  
Why don't most EM have the Target appearance  
Comparison of Infrared photo vs. Visible light





# Thermal Enhancement Example

Anecdotal stories of rashes that only appear after hot shower or in the direct sun light

Possible use of “hot and cold shower” to bring out otherwise unseen EM rash

**Room Temperature**



**After Warm Shower**




# Thermal Enhancement of Erythema Migrans

protocol of Henry G Taylor MD MPH.

- Expose to room air for five minutes to even out skin temperature and pressure marks.
- Take a cell-phone picture at room temperature
- Take a warm shower. Warm enough to make your skin feel flushed, but NOT scalding!
- Pat rash dry – DO NOT RUB or irritate rash.
- Take second cell-phone picture
- Take a cool shower. It should feel cold and skin should look more pale than usual.
- Pat rash dry – DO NOT RUB or irritate rash.
- Take third cell-phone picture
- Email the pictures to your doctor

# Post-Treatment Lyme Disease Syndrome:

Fatigue, widespread pain, cognitive difficulties  
("subject complaints")



# Post Treatment Follow Up


- Measures of cure based on physical exam to document resolution of rash
  - Serology not biomarker for “proof of cure”
- Follow up visits
  - What to look for
    - Persistence of rash or other findings
    - Evidence of neurologic complication
    - Post treatment symptoms
- Expectations of post treatment health
  - Anticipatory guidance for patients on how symptoms are likely to resolve


---

---

Severe Fatigue  
Cutoff = 20

# Total Beck Depression Index





Line Indicates  
A Composite  
Score of 45



# Patient Follow Up after Treatment of Lyme Disease


## **Anticipatory Guidance**

- Treat with Doxycycline for three weeks. Further antibiotics not needed unless there are obvious signs or symptoms of continued illness.
- Follow-up in 3 weeks to confirm rash cleared and assess symptoms/relapse.
- Empathetic Non-Judgmental listening to elicit patient beliefs and goals.
- Self-Care is important, especially rest and moderate exercise.
- Follow-up in 7 weeks to discuss persistent symptoms and potential benefit of exercise, lifestyle changes and/or Integrative Medicine treatments.

Developed in collaboration with Henry G Taylor MD MPH.

# National Institute of Standards and Technology Workshop on Measurement in Lyme Disease

- Discussion of a variety of promising technologies and techniques for addressing the measurement of Lyme disease.
- Promotion of awareness, research collaboration and creative solutions
- Accelerate the time to development of effective biomarkers needed for more reliable diagnosis and management of the different stages of Lyme disease.



The poster features a header with four images: a tick on a green background with the NIST logo, microscopic views of spirochetes, a tick on a yellow background, and a person in blue gloves using tweezers to handle a petri dish. The main text is on a blue background with a hexagonal pattern.

**Please join us**  
June 6, 2013 | 8:30 am - 5:30 pm  
The National Institute of Standards and Technology (NIST)  
Gaithersburg, MD

**Measurement – The Foundation for the Effective  
Diagnosis and Management of Lyme Disease**

The National Institute of Standards and Technology (NIST) invites you to a Lyme Disease Workshop on June 6<sup>th</sup>, 2013. The Workshop will be focused on the challenges of measurement in Lyme disease. The goal of this workshop is to accelerate the development of sensitive and specific tests for Early Lyme disease and Post-Treatment Lyme Disease Syndrome.

**Confirmed Topics and Speakers:**

NIST Supporting Measurements for Clinical Diagnostics	Willie E. May, PhD, NIST
Keynote Address: Setting the Stage	John Aucott, MD, Johns Hopkins University
Clinical and Laboratory Challenges of Lyme Disease Diagnostics	Adriana Marques, MD, NIH-NIAID
Improved Serology	Phil Felgner, PhD, University of California, Irvine
DNA Detection	Mark Eshoo, PhD, Ibis Biosciences, Inc., Abbott Laboratories
Cellular- and Cytokine-based Immunoassays	Linda Bockenstedt, MD, Yale University
Nanotechnology	A.T. Charlie Johnson, PhD, University of Pennsylvania
Biorepository Needs and Possibilities	Lunch roundtable discussion
RNA Detection and Transcriptomics	Charles Chiu, MD/PhD, University of California, San Francisco
Mass Spectrometry and Metabolomics	John Belisle, PhD, Colorado State University
Culture	Steve Dumler, MD, Johns Hopkins University
Imaging	Niren Murthy, PhD, University of California, Berkeley

*Time will also be provided for breakout sessions for discussion of research topics.*

**Organizing Committee:**

Laurie Locascio, PhD, NIST	Mary Satterfield, PhD, NIST
John Aucott, MD, Johns Hopkins University	David Roth, JD, Tick-Borne Disease Alliance
Joseph Breen, PhD, NIH-NIAID	Carin Rollins, MBA, Bay Area Lyme Foundation
James Serum (Chair), PhD, Scitek Ventures (retired)	

<http://www.nist.gov/mml/nist-workshop-on-lyme-disease.cfm>